Ascent Scientific has announced the availability of the first commercial source of TMCB – a new kinase inhibitor that is selective for CK2. It is more selective than the prototypic CK2 inhibitor DMAT over a range of other kinases.
Steve Roome, commercial director of Ascent Scientific, said: Ascent Scientific is proud to be the first life science supplier to make this exciting kinase inhibitor commercially available to the scientific community. Up until now, many researchers have used DMAT to inhibit CK2. However, unlike DMAT, TMCB displays selectivity over PIM1, HIPK2 and DYRK1a and displays a more favourable selectivity profile over a range of other kinases.
Iain Sandison, science director of Ascent Scientific, said: TMCB is available at very high purity (at least 99%). And of course, in keeping with our philosophy, we have introduced it at an affordable price!